早发型间质性肺病的分子遗传学诊断:699例无关患者的结果
该研究在6年间对699例早发型ILD先证者及190名亲属进行Sanger测序和/或靶向二代测序,检测表面活性物质相关基因及其他相关基因。62例(8.9%)检出致病/可能致病变异,最常见为SFTPA2、ABCA3和SFTPC。研究识别了与高分子诊断率相关的临床特征,并强调分子诊断对遗传咨询的重要性。
要点
- 早发型ILD患者中8.9%可检出致病/可能致病变异,以SFTPA2、ABCA3、SFTPC最常见。
- 肺泡蛋白沉积症、ILD/肺纤维化及肺癌家族史、>32周新生儿呼吸窘迫与高诊断率相关。
- 分子诊断阳性率在1-10岁儿童(23.3%)和30-40岁成人(18.3%)两个年龄段较高。
核心结论
- 早发型ILD患者中8.9%(62/699)检出致病/可能致病变异。
- 研究识别了与高或低分子诊断率相关的特定患者特征。
- 强调建立分子诊断对家庭遗传咨询的重要性。
研究设计与样本
- 研究纳入699例早发型ILD先证者(新生儿至<50岁年轻成人)和190名亲属。
- 在6年间对表面活性物质相关基因和其他早发型ILD相关基因进行Sanger测序和/或靶向二代测序。
- 对190名亲属进行共分离研究(n=123)和/或预测性检测(n=79)。
主要发现
- 62例(8.9%)检出致病/可能致病变异。
- 最常涉及基因为SFTPA2(13/62),其次ABCA3(12/62)和SFTPC(10/62)。
- 在542例有精确临床数据的先证者中,高诊断率相关因素包括:肺泡蛋白沉积症61.5%(8/13;p<0.0007)、ILD/肺纤维化及肺癌家族史36.8%(7/19;p=0.0132)、>32周妊娠新生儿呼吸窘迫14.8%(9/61)。
- 分子诊断阳性率在两个年龄段较高:1-10岁儿童23.3%(7/30),30-40岁成人18.3%(15/82)。
关键数值与推荐
- 总体分子诊断率8.9%(62/699)。
- 肺泡蛋白沉积症患者诊断率61.5%(8/13;p<0.0007)。
- ILD/肺纤维化及肺癌家族史者诊断率36.8%(7/19;p=0.0132)。
- >32周妊娠新生儿呼吸窘迫者诊断率14.8%(9/61)。
- 1-10岁儿童诊断率23.3%(7/30),30-40岁成人18.3%(15/82)。
临床怎么用
- 对早发型ILD患者应评估家族史及临床特征(如肺泡蛋白沉积症、新生儿呼吸窘迫)以指导基因检测。
- 检出致病/可能致病变异后可为家庭提供遗传咨询。
- 对亲属可进行共分离研究或预测性检测。
局限性
- 仅542例先证者有精确临床数据用于诊断率相关因素分析,其余病例数据不全。
- 研究为单中心参考实验室经验,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Interstitial lung diseases (ILDs) are rare and severe respiratory conditions that may ultimately result in pulmonary fibrosis (PF). The objective of this study was to present the results of molecular diagnosis of early-onset ILD (from neonates to young adults < 50 years) in a reference genetic diagnostic laboratory. METHODS: DNAs from 699 index cases and 190 relatives were studied over 6 years by Sanger and/or targeted next generation sequencing of surfactant-related genes and other genes involved in early-onset ILD. RESULTS: Pathogenic/likely pathogenic variants were evidenced for 62 patients (8.9%). The genes most frequently involved were SFTPA2 (13/62), followed by ABCA3 (12/62) and SFTPC (10/62). Among index cases for whom precise clinical data were available (n = 542), indications associated with a high molecular diagnostic yield were pulmonary alveolar proteinosis (61.5%, 8/13; p < 0.0007); family history of ILD/PF and lung cancer (36.8%, 7/19; p = 0.0132) and newborns > 32 weeks gestation with neonatal respiratory distress (14.8%, 9/61). The proportion of positive molecular investigations culminated in two age groups over the lifespan: 23.3% (7/30) in children aged 1 to 10 years, and 18.3% (15/82) in adults aged 30 to 40 years. Over the 6-year period, 190 relatives were subjected to testing in order to perform segregation studies (n = 123) and/or predictive testing (n = 79). CONCLUSION: This study highlights the specific patient's characteristics associated with a high or low molecular diagnostic yield in clinical practice. Furthermore, it emphasises the importance of establishing a molecular diagnosis in order to provide genetic counselling to the family.
引用
- Louvrier C, Nathan N, Cottin V, et al. Molecular Investigation in Early-Onset Interstitial Lung Disease: Results From 699 Unrelated Patients. Respirology. 2025. PMID: 41041870. doi:10.1111/resp.70132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。